Skip to main content
. Author manuscript; available in PMC: 2014 Sep 14.
Published in final edited form as: J Urol. 2013 Oct 29;191(4):1153–1158. doi: 10.1016/j.juro.2013.10.102

Figure 1.

Figure 1

Representative images show immunohistochemical localization of CB2-like immunoreactivity in bladder urothelium of mice treated with saline, acrolein, acrolein plus GP1a and acrolein plus AM630 plus GP1a (A). Scale bar indicates 50 μm. Immunoblot reveals that neither cystitis nor treatment with GP1a or AM630 plus GP1a altered CB2-like immunoreactivity abundance in urothelium (B and C). GAPDH, glyceraldehyde 3-phosphate dehydrogenase (B). Values represent mean ± SEM of 6 saline treated controls and 8 mice with other treatment (C).